Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe

Phase 3

Completed

• Conditions: Arthritis, Rheumatoid
• Interventions: Drug: Methotrexate

• Registration Number: NCT02553018
• Lead Sponsor: Nordic Pharma SAS

Brief Summary

The primary objective of the study is to compare, in patients treated with methotrexate injection for rheumatoid arthritis, the compliance and the health assessment questionnaire evolution for the administration by auto-injector versus administration by conventional subcutaneous injection, after 6 months of treatment.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2015-09
• Study First Submitted: 2015-09-16
• Study First Submitted QC: 2015-09-16
• Study First Posted: 2015-09-17
• Primary Completion: 2017-08
• Study Completion: 2017-08
• Status Verified: 2017-10
• Last Update Submitted: 2017-10-05
• Last Update Posted: 2017-10-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 278

Inclusion Criteria

• Adult patient (18 years or over) of either sex.
• With established rheumatoid arthritis diagnosis
• Treated for rheumatoid arthritis by methotrexate (oral or by injection) since at least 3 months regardless of the prior or combined disease modifying treatment, except biotherapies and justifying injection of methotrexate. For the patient treated by oral methotrexate, the switch decided by the rheumatologist is made for either safety, compliance or efficacy issues.
• Agreeing to participate in the study and having dated and signed the informed consent form.

Read More

Exclusion Criteria

• Patients fulfilling one or more of the following exclusion criteria will not be included in the study:

  • Inability of patient to use an auto-injector.
  • Treated with biotherapies.
  • Pregnant or breast-feeding patients
  • Male and female patients with reproductive potential who are not willing to use effective method of contraception (oral contraceptives, intrauterine device, condoms) during study and at least 1 month after the end of the study.
  • Patients with :

• hypersensitivity to methotrexate or to any of the excipients,

• severe hepatic impairment,

• alcohol abuse,

• severe renal impairment,

• pre-existing blood dyscrasias, such as bone marrow hypoplasia, leukopenia, thrombocytopenia or significant anaemia,

• Immunodeficiency,

• serious, acute or chronic infections such as tuberculosis and HIV,

• stomatitis, ulcers of the oral cavity and known active gastrointestinal ulcer disease,

• concurrent vaccination with live vaccines.

  • Association with probenecid, trimethoprim, phenylbutazone.
  • Any other known medical or surgical history, disorder or disease judged by the investigator to be incompatible with the study (such as acute or chronic severe organic disease: hepatic, endocrine, neoplasia, haematological, infectious diseases, severe psychiatric illness, relevant cardiovascular abnormalities, etc...),
  • Inability of patient to understand the study procedures and thus inability to give informed consent.
  • Participation in another clinical study, at the same time as the present study, or during the month following the end of the previous study
  • Ward of court.
  • Patient not covered by the Social Security.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Pre-filled syringe of methotrexate	Methotrexate	Pre-filled syringes contains a volume of 1 ml with attached injection needle. Dosage form: solution for injection. Dosage: 0.15 ml contains 7.5 mg of methotrexate, 20 ml contains 10 mg of methotrexate, 0.30 ml contains 15 mg of methotrexate, 0.40 ml contains 20 mg of methotrexate, 0.50 ml contains 25 mg of methotrexate disodium. Frequency: one injection per week Duration: until the end of the study
Auto-injector of methotrexate	Methotrexate	The Auto-injector is a disposable, fixed, single dose, auto-injector to be used for Methotrexate (25mg/ml) therapy. Dosage form: solution for injection Dosage: 0.3ml contains 7.5mg of Methotrexate, 0.4ml contains the 10.0mg of Methotrexate, 0.6ml contains 15.0 mg of Methotrexate, 0.8ml contains 20.0 mg of Methotrexate, 1.0ml contains 25.0 mg of Methotrexate. Frequency: one injection per week Duration: until the end of the study

Primary Outcome Measures

Name	Time	Method
Co-primary criteria: observance and health assessment questionnaire	6 months	the health assessment questionnaire is completed by the patient at inclusion visit and at the 6 months visit. Compliance with methotrexate treatment will be assessed by the investigator at each visit

Secondary Outcome Measures

Name	Time	Method
quality of life	6 months	Patient's quality of life will be assessed using a validated questionnaire. completed by the patient at inclusion and 6 months visits. Change from baseline in questionnaire score will be described.
acceptability	up to 1 year	The product acceptability will be evaluated by the patient using a specific questionnaire based on several questions related to the patient' opinion, satisfaction and willingness to adopt the product.
preference	6 months	Preference will be assessed only for patients receiving auto-injector and pre-filled syringe of methotrexate
Economic	6 months	Information on the consumed resources for methotrexate administration will be assessed at 6 months. This information will be further incorporated in a budget impact for the French Sickness Fund

Trial Locations

Locations (2)

SARAUX; 🇫🇷 Brest, France

HUDRY; 🇫🇷 Paris, France